Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development, and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma and other diseases of the eye, today announced the appointments
of Nils Hauptmann as Director of Regulatory Affairs and
Pharmacovigilance, reporting to Cindy Martin, Aerie’s Vice President of
Regulatory, and Tim Swan as Director of Sales and Transparency
Operations, reporting to Gerry McKenzie, Aerie’s Vice President of
Commercial Operations. Mr. Hauptmann will support the preparation of
regulatory and clinical documents along with oversight of post-marketing
pharmacovigilance and promotional activities. Mr. Hauptmann previously
held related positions at Avanir Pharmaceuticals, Inc. and Fibrogen,
Inc. Mr. Swan will lead the operational functions in support of teams
that interact with healthcare providers and organizations. Mr. Swan
previously held related positions at Allergan, Inc.

In connection with the acceptance of their positions, Mr. Hauptmann and
Mr. Swan on a combined basis will receive awards totaling 28,800 stock
options. The stock options will vest over 4 years, with 25% vesting on
the first anniversary of the hire date and the remainder vesting ratably
on each of the subsequent 36 monthly anniversaries of the hire date.
These awards were made outside of Aerie’s stockholder-approved equity
incentive plan and were approved by the Company’s independent directors
as inducements material to Mr. Hauptmann and Mr. Swan entering into
employment with the Company in reliance on NASDAQ Listing Rule
5635(c)(4), which requires this public announcement.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma and other diseases of the
eye. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution)
0.02%, for the reduction of elevated intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular hypertension, was approved
by the U.S. Food and Drug Administration (FDA) in December 2017. A link
to the full product label is available on the Aerie website at http://investors.aeriepharma.com.
Aerie’s second product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a
fixed dose combination of Rhopressa® and widely prescribed
PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3
registration trials, named Mercury 1 and Mercury 2, and also achieved
successful 12-month safety and efficacy results in Mercury 1. The
RoclatanTM NDA submission is expected to take place in the
second quarter of 2018. Aerie is also focused on global expansion and
the development of additional product candidates and technologies in
ophthalmology.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should,” “exploring,” “pursuing” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the
success, timing and cost of our ongoing and anticipated preclinical
studies and clinical trials for our current product candidates,
including statements regarding the timing of initiation and completion
of the studies and trials; our expectations regarding the clinical
effectiveness of our product candidates and results of our clinical
trials; the timing of and our ability to request, obtain and maintain
FDA or other regulatory authority approval of, or other action with
respect to, our product candidates, including the expected timing of,
and timing of regulatory and/or other review of, filings for our product
candidates; our expectations regarding the commercialization of our
product candidates; the potential advantages of our product candidates;
our plans to pursue development of our product candidates for additional
indications and other therapeutic opportunities; our plans to explore
possible uses of our existing proprietary compounds beyond glaucoma; our
ability to protect our proprietary technology and enforce our
intellectual property rights; and our expectations regarding strategic
operations, including our ability to in-license or acquire additional
ophthalmic products or product candidates or technologies. By their
nature, forward-looking statements involve risks and uncertainties
because they relate to events, competitive dynamics, industry change and
other factors beyond our control, and depend on regulatory approvals and
economic and other environmental circumstances that may or may not occur
in the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under the
heading “Risk Factors” in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). In particular, FDA
approval of Rhopressa® does not constitute approval of RoclatanTM,
and there can be no assurance that we will receive FDA approval for
RoclatanTM or any future product candidates. Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ materially
from the forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her
physician.